The ACIP develops recommendations on how to use vaccines to control disease in the United States.
The Committee’s recommendations are forwarded to CDC’s Director for approval. Once the ACIP recommendations have been reviewed and approved by the CDC Director and the U.S. Department of Health and Human Services, they are published in CDC’s Morbidity and Mortality Weekly Report (MMWR). The MMWR publication represents the final and official CDC recommendations for immunization of the U.S. population.
Professional organizations that work with the ACIP to develop the annual childhood and adult schedules include the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), the American College of Obstetricians and Gynecologists (ACOG), and the American College of Physicians (ACP).
- ACIP Recommendations
Complete list of ACIP recommendations published in the MMWR.
- Immunization Schedules
Links to the childhood, adolescent, catch-up, and adult immunization schedules; plus vaccine recording and screening forms.
- ACIP Shared Clinical Decision-Making FAQs
Frequently asked questions about ACIP’s recommendations based on shared clinical decision-making
ACIP approved the following recommendations by majority vote at its June 22-23, 2022 meeting:
- ACIP recommends that adults aged ≥65 years preferentially receive one of the following influenza vaccines: quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (aIIV4). If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be used.
- Affirm the updated MMWR Recommendations and Reports, “Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2022-23 Influenza Season.”
- PCV15 (15-valent pneumococcal conjugate vaccine) may be used as an option to PCV13 (13-valent pneumococcal conjugate vaccine) for children aged <19 years according to currently recommended PCV13 dosing and schedules.
- MMR vaccine (Priorix, GSK) according to currently recommended schedules and off-label uses as an option to prevent measles, mumps, and rubella.
These recommendations have been adopted by the CDC Director and will become official once published in MMWR.